Knight Capital Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Knight Capital Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$941K	Buy	+27,075	New	+$951K	0.02%	1070

Other funds holding XBI

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MSA

Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return

ING Group Amsterdam, Netherlands $16.4B AUM 34.6% 1-Year Est. Return

Knight Capital Group's XBI Position: Q2 2013 in Review

Knight Capital Group opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2013: 27,075 shares worth $941K. The stake represents 0.02% of the portfolio and ranks #1070 among its holdings.

123 funds tracked by Wall St. Rank hold XBI as of Q2 2013.

Knight Capital Group held 27,075 shares of State Street SPDR S&P Biotech ETF worth $941K as of Q2 2013.
State Street SPDR S&P Biotech ETF was a new Knight Capital Group position in Q2 2013.
State Street SPDR S&P Biotech ETF made up 0.02% of Knight Capital Group's portfolio in Q2 2013, its #1070 holding.
123 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.